Cost effectiveness of elidel in the management of patients with atopic dermatitis in Canada

Journal of Cutaneous Medicine and Surgery

Volumn 8, Issue 6, 2004, Pages 405-410

  Coyle, Douglas ^a,b   Barbeau, Martin ^c  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c Novartis Pharmaceuticals Canada Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; EMOLLIENT AGENT; PIMECROLIMUS;

ADOLESCENT; ADULT; ARTICLE; ATOPIC DERMATITIS; CANADA; CHILD; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; ECZEMA; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CANADA; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; HUMANS; TACROLIMUS;

EID: 26244445627     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10227-004-0111-y     Document Type: Article

References (22)

1. KA Knoell KE. Greer 1999 Atopic dermatitis Pediatr Rev 20 46 52
2. K. Thestrup-Pedersen 2000 Clinical aspects of atopic dermatitis Clin Exp Dermatol 25 535 543
3. L Diepgen M. Fartasch 1992 Recent epidemiological and genetic studies in atopic dermatitis Acta Derm Venereol 176 13 -18
4. National Eczema Association. All about atopic dermatitis. National Eczema Association 2002; 25-4-0001
5. NH. Nicol 2000 Managing atopic dermatitis in children and adults Nurse Pract 25 58 79
6. H Williams C Robertson A Stewart 1999 Worldwide variations in the prevalence of symptoms of atopic eczema in the international study of asthma and allergies in childhood J Allergy Clin Immunol 103 125 138
7. CN Ellis LA Drake MM Pendergast 2002 Cost of atopic dermatitis and eczema in the United States J Am Acad Dermatol 46 361 370
8. RM Herd MJ Tidman RJ Prescott 1996 The cost of atopic eczema Br J Dermatol 135 20 23
9. RM Emerson HC Williams BR. Alien 2001 What is the cost of atopic dermatitis in preschool children? Br J Dermatol 144 514 522
10. CS Lapidus DF Schwarz PJ. Honig 1993 Atopic dermatitis in children: who cares? who pays? J Am Acad Dermatol 28 699 703
11. JC Su AS Kemp GS Varigos 1997 Atopic eczema: its impact on the family and financial cost Arch Dis Child 76 159 162
12. Novartis Pharmaceuticals Canada Inc. Elidel (pimecrolimus) product monograph, 2003
13. A. Laupacis 2002 Inclusion of drugs in provincial drug benefit programs: Who is making these decisions, and are they the right ones? Can Med Assoc J 166 44 47
14. GW. Torrance 1986 Measurement of health state utilities for economic evaluation-a review J Health Econ 5 1 30
15. Barbeau M, Lalonde H. Burden of illness of eczema in Canada. ISPOR 8th Annual International Meeting, May 2003
16. Byam J, Friedman J, Reed S, et al. Patient preferences for children suffering from atopic dermatitis. Centre for Clinical and Genetic Economics, Duke Clinical Research Institute, 2002
17. GW Torrance DH Feeny WJ Furlong 1996 Multi-attribute preference functions for a comprehensive health status classification system: Health Utilities Index Mark 2 Med Care 34 702 722
18. GW. Torrance 1976 Social preferences for health states: an empirical evaluation of three measurement techniques Socioecon Plan Sci 10 129 136
19. A Briggs M Schulper M. Buxton 1994 Uncertainty in the economic evaluation of health care technologies-the role of sensitivity analysis Health Econ 3 95 104
20. A Laupacis D Feeny AS Detsky 1992 How attractive does a new technology have to be to warrant adoption and utilization. Tentative guidelines for using clinical and economic evaluations Can Med Assoc J 146 473 481
21. DN Churchill DC Lemon GW. Torrance 1984 Cost-effectiveness analysis comparing continuous ambulatory peritoneal dialysis to hospital hemodialysis Med Decis Making 4 489 500
22. V Goel RB Deber AS. Detsky 1989 Nonionic contrast media: economic analysis and health policy development Can Med Assoc L 140 389 395